Safety and effectiveness of IPN60300 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has spread or cannot be removed with surgery, and standard treatments no longer work or are not an option.
- Your tumor must be measurable on scans.
- You must be able to take care of yourself (up and about more than 50% of waking hours).
- You need to provide a sample of your tumor tissue for testing.
- You must have adequate bone marrow, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.